Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus

PLoS Neglected Tropical Diseases

Volumn 1, Issue 3, 2007, Pages

  Brandler, Samantha ^a   Lucas Hourani, Marianne ^b   Moris, Arnaud ^a   Frenkiel, Marie Pascale ^b   Combredet, Chantal ^a   Février, Michèle ^a   Bedouelle, Hugues ^a   Schwartz, Olivier ^a   Desprès, Philippe ^b   Tangy, Frédéeric ^a  

^a CNRS   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; DENGUE VIRUS ANTIGEN; MEASLES VACCINE; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEDIATRICS; PROTECTION; PROTEIN DOMAIN; SEROTYPE; TROPICS; VERO CELL; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CELL SURVIVAL; CERCOPITHECUS; DENGUE; DENGUE VIRUS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CYTOKINES; DENDRITIC CELLS; DENGUE; DENGUE VIRUS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOLOGIC MEMORY; MEASLES VACCINE; MICE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VERO CELLS; VIRUS REPLICATION;

EID: 47749147699     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000096     Document Type: Article

References (59)

1. Mackenzie JS, Gubler DJ, Petersen LR (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: S98-109.
2. Catteau A, Kalinina O, Wagner MC, Deubel V, Courageot MP, et al. (2003) Dengue virus M protein contains a proapoptotic sequence referred to as ApoptoM. J Gen Virol 84: 2781-2793.
3. Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42: 311-328.
4. Halstead SB, O'Rourke EJ (1977) Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265: 739-741.
5. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986-6991.
6. Modis Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79: 1223-1231.
7. Crill WD, Chang GJ (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78: 13975-13986.
8. Simmons M, Nelson WM, Wu SJ, Hayes CG (1998) Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58: 655-662.
9. Hermida L, Rodriguez R, Lazo L, Bernardo L, Silva R, et al. (2004) A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 39: 107-114.
10. Hermida L, Rodriguez R, Lazo L, Silva R, Zulueta A, et al. (2004) A dengue-2 Envelope fragment inserted within the structure of P64K meningococcal protein carrier enables a functional immune response against the virus in mice. Journal of Virological Methods 115: 41-49.
11. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, et al. (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24: 3165-3171.
12. Khanam S, Etemad B, Khanna N, Swaminathan S (2006) Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg 74: 266-277.
13. Griffin D (2001) Measles virus. In: Knipe D, Howley P, eds. Field's Virology, 4th Edition. Philadelphia: Lippincott-Raven Publishers. pp 1401-1441.
14. Naniche D, Garenne M, Rae C, Manchester M, Buchta R, et al. (2004) Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J Infect Dis 190: 1387-1395.
15. Ovsyannikova I, Dhiman N, Jacobson R, Vierkant R, Poland G (2003) Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clinical and Diagnostic Laboratory Immunology 10: 411-416.
16. Combredet C, Labrousse-Najburg V, Mollet L, Lorin C, Delebecque F, et al. (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. Journal of Virology 77: 11546-11554.
17. Lorin C, Delebecque F, Labrousse V, Da Silva L, Lemonnier F, et al, (2005) A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV 1 conserved epitopes. Vaccine 23: 4463-4472.
18. Lorin C, Mollet L, Delebecque F, Combredet C, Charneau P, et al. (2004) A Single Injection of Recombinant Measles Vaccines Expressing HIV-1 Clade B Envelope Glycoproteins Induces Neutralizing Antibodies and Cellular Immune Responses to HIV. Journal of Virology 78: 146-157.
19. Desprès P, Combredet C, Frenkiel M, Lorin C, Brahic M, et al. (2005) Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. Journal of Infectious Diseases 191: 207-214.
20. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, et al. (1995) Rescue of measles viruses from cloned DNA. Embo J 14: 5773-5784.
21. Goxe B, Latour N, Bartholeyns J, Romet-Lemonne JL, Chokri M (1998) Monocyte-derived dendritic cells: development of a cellular processor for clinical applications. Res Immunol 149: 643-646.
22. Moris A, Pajot A, Blanchet F, Guivel-Benhassine F, Salcedo M, et al. (2006) Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer. Blood 108: 1643-1651.
23. Despres P, Frenkiel MP, Ceccaldi PE, Duarte Dos Santos C, Deubel V (1998) Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses. J Virol 72: 823-829.
24. Calain P, Roux L (1993) The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67: 4822-4830.
25. Parks CL, Lerch RA, Walpita P, Sidhu MS, Udem SA (1999) Enhanced measles virus cDNA rescue and gene expression after heat shock. J Virol 73: 3560-3566.
26. Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75: 7769-7773.
27. Duarte dos Santos CN, Frenkiel MP, Courageot MP, Rocha CF, Vazeille-Falcoz MC, et al. (2000) Determinants in the envelope E protein and viral RNA helicase NS3 that influence the induction of apoptosis in response to infection with dengue type 1 virus. Virology 274: 292-308.
28. Deubel V, Kinney RM, Trent DW (1988) Nucleotide sequence and deduced amino acid sequence of the nonstructural proteins of dengue type 2 virus, Jamaica genotype: comparative analysis of the full-length genome. Virology 165: 234-244.
29. Sambrook J, Russell DW (2001) Molecular Cloning: A Laboratory Manual.
30. Bedouelle H, Belkadi L, England P, Grujarro JI, Lisova O, et al. (2006) Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus. Febs J 273: 34-46.
31. Lucas M, Mashimo T, Frenkiel M-P, Simon-Chazottes D, Montagutelli X, et al. (2003) Infection of mouse neurons by West Nile virus is modulated by the interferon-inducible 2′-5′ oligoadenylate synthetase 1b protein. Immun Cell Biol 81: 230-236.
32. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, et al. (2003) Dendritic-cell-specific, ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4: 723-728.
33. Thullier P, Demangel C, Bedouelle H, Mégret F, Jouan A, et al. (2001) Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralizing mechanism. Journal of General Virology 82: 1885-1892.
34. Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, et al. (1998) Measles virus spread and pathogenesis in genetically modified mice. J Virol 72: 7420-7427.
35. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
36. Singh M, Cattaneo R, Billeter MA (1999) A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73: 4823-4828.
37. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
38. Grosjean I, Caux C, Bella C, Berger I, Wild F, et al. (1997) Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. J Exp Med 186: 801-812.
39. Klagge IM, ter Meulen V, Schneider-Schaulies S (2000) Measles virus-induced promotion of dendritic cell maturation by soluble mediators does not overcome the immunosuppressive activity of viral glycoproteins on the cell surface. Eur J Immunol 30: 2741-2750.
40. Schnorr JJ, Xanthakos S, Keikavoussi P, Kampgen E, ter Meulen V, et al. (1997) Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression. Proc Natl Acad Sci U S A 94: 5326-5331.
41. Servet-Delprat C, Vidalain PO, Bausinger H, Manie S, Le Deist F, et al. (2000) Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells. J Immunol 164: 1753-1760.
42. Zilliox MJ, Parmigiani G, Griffin DE (2006) Gene expression patterns in dendritic cells infected with measles virus compared with other pathogens. Proc Natl Acad Sci U S A 103: 3363-3368.
43. Mahalingam S, Clark K, Matthaei KI, Foster PS (2001) Antiviral potential of chemokines. Bioessays 23: 428-435.
44. Sallusto F, Lanzavecchia A (1999) Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunological reviews 177: 134-140.
45. Sallusto F, Palermo B, Lenig D, Miettinen M, Matikainen S, et al. (1999) Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 29: 1617-1625.
46. Kurane I, Ennis FA (1997) Immunopathogenesis of dengue virus infections, in Dengue and Dengue Hemorrhagic Fever (eds. Gubler, D.J. and Kuno G.). CAB International, London. pp 273-290.
47. Stephenson JR (1998) Flavivirus vaccines. Vaccine. pp 471-480.
48. Johnson AJ, Roehrig JT (1999) New mouse model for dengue virus vaccine testing. J Virol 73: 783-786.
49. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208-10217.
50. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG (2007) A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 195: 665-674.
51. Mota J, Acosta M, Argotte R, Figureueroa R, Mendez A, et al. (2005) Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23: 3469-3476.
52. Khanam S, Khanna N, Swaminathan S (2006) Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24: 6513-6525.
53. Khanam S, Rajendra P, Khanna N, Swaminathan S (2007) An adenovirus prime/ plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol 7: 10.
54. Chu JHJ, Chiang CCS, Ng ML (2007) Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol 178: 2699-2705.
55. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, et al. (2007) A West Nile Virus Recombinant Protein Vaccine That Coactivates Innate and Adaptative Immunity. The Journal of Infectious Diseases 195: 1607-1617.
56. Blander JM, Medzhitov R (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440: 808-812.
57. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, et al. (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
58. Tangy F, Naim H (2005) Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 18: 317-326.
59. Saluzzo JF (2003) Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Adv Virus Res 61: 419-443.